Epizyme (NASDAQ:EPZM) – Analysts at Leerink Swann dropped their FY2022 earnings per share estimates for shares of Epizyme in a research note issued to investors on Tuesday, March 13th, according to Zacks Investment Research. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will earn $3.46 per share for the year, down from their prior estimate of $3.86. Leerink Swann currently has a “Outperform” rating and a $24.00 target price on the stock.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.05. The firm’s revenue for the quarter was down 100.0% compared to the same quarter last year.
EPZM has been the subject of a number of other reports. Zacks Investment Research cut Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a report on Tuesday, February 13th. Jefferies Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Epizyme in a report on Wednesday, January 24th. Cann reissued a “buy” rating and set a $26.00 price objective on shares of Epizyme in a report on Tuesday, December 12th. Finally, BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $23.50.
Epizyme stock opened at $14.85 on Thursday. Epizyme has a 12-month low of $9.30 and a 12-month high of $21.40. The stock has a market capitalization of $1,135.35, a P/E ratio of -6.81 and a beta of 1.96.
Several institutional investors have recently bought and sold shares of EPZM. Teacher Retirement System of Texas acquired a new position in shares of Epizyme during the 4th quarter worth about $202,000. Fox Run Management L.L.C. grew its position in shares of Epizyme by 64.7% during the 4th quarter. Fox Run Management L.L.C. now owns 19,275 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 7,575 shares during the period. Bailard Inc. acquired a new position in shares of Epizyme during the 4th quarter worth about $251,000. MetLife Investment Advisors LLC acquired a new position in shares of Epizyme during the 4th quarter worth about $263,000. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Epizyme during the 3rd quarter worth about $292,000. Institutional investors own 85.88% of the company’s stock.
In other news, COO Matthew Ros sold 72,264 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the completion of the transaction, the chief operating officer now directly owns 74,867 shares in the company, valued at approximately $1,245,038.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 25.20% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Leerink Swann Analysts Decrease Earnings Estimates for Epizyme (EPZM)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/leerink-swann-comments-on-epizyme-incs-fy2022-earnings-epzm.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Get a free copy of the Zacks research report on Epizyme (EPZM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.